The board of directors at Sanofi unanimously agree to remove Sanofi's CEO.
Christopher A. Viehbacher resigned as director of Sanofi immediately after its Board of Directors unanimously agreed to remove him as the company’s CEO on Oct. 29, 2014. Chairman Serge Weinberg will replace Viehbacher on an interim basis.
Weinberg toldFinancial Times in an interview that the 15-member board at Sanofi was generally dissatisfied with Viehbacher’s performance at the company and there were “some worries about management style, about execution, focus, and also about the nature of the relationship with the board.” According to this interview, the board had been contemplating the decision to oust Viehbacher since last summer, although Sanofi initially said in a meeting to review quarterly results earlier this week that replacing the CEO was not on the meeting’s agenda. In addition to dissatisfaction, inventory mismanagement in Brazil was also reportedly a key factor in the board’s decision.
The announcement comes just one day after Reutersreported Sanofi would face increased pricing pressure on its diabetes portfolio. Diabetes medications, one of Sanofi’s key growth areas, face increased pricing and rebate pressure now that many health insurance formularies are eliminating similar products in competing classes. Sanofi's drug Lantus, which accounts for a third of operating profit according to Reuters, is slated to lose patent protection in early 2015.
“Going forward, the Group needs to pursue its development with a management aligning the teams, harnessing talents and focusing on execution with a close and confident cooperation with the Board,” Weinberg said in a company statement.
Source:
Sanofi
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.